Efficacy and Safety Study of Egg Yolk Antibody in Adjuvant Treatment of Helicobacter Pylori Infection
NCT05410223 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2022-12-09
Summary
Helicobacter pylori is an important pathogenic factor for gastrointestinal diseases such as gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer.However, with the increasing use of antibiotics, antibiotic resistance of Helicobacter pylori continues to rise. In this study, we used egg yolk antibody combined with bismuth quadruple therapy to treat patients with Helicobacter pylori infection, and observed the eradication rate of Helicobacter pylori, the relief of clinical symptoms and the incidence of adverse reactions.
Conditions
- Helicobacter Pylori Infection
Interventions
- DRUG
-
Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd. Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd. Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd. Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd. Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd. bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
- DRUG
-
IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth
Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd. Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd. Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd. Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd. bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
- DRUG
-
Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline
Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd. Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd. Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd. Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd. Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.
- DRUG
-
IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd. Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd. Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd. Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd. bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Sponsors & Collaborators
-
The Third Xiangya Hospital of Central South University
lead OTHER
Principal Investigators
-
SHA CHENG · The Third Xiangya Hospital of Central South University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-06
- Primary Completion
- 2022-12-01
- Completion
- 2022-12-01
Countries
- China
Study Locations
More Related Trials
-
Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach
NCT00002682 ·Status: COMPLETED ·Phase: PHASE2
-
Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin
NCT04122287 ·Status: UNKNOWN ·Phase: PHASE4
-
ILTHPI - Comparison of Medicament Containing Tetracycline, Metronidazole, Bismuth Versus Amoxicillin, Metronidazole, Clarithromycin
NCT04853875 ·Status: COMPLETED ·Phase: PHASE4
-
Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.
NCT05432115 ·Status: UNKNOWN ·Phase: PHASE4
-
Doxycycline for Helicobacter Pylori Rescue Treatment
NCT05874570 ·Status: RECRUITING ·Phase: PHASE4
-
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
NCT04558502 ·Status: UNKNOWN ·Phase: PHASE4
-
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
NCT04527055 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection
NCT02689583 ·Status: UNKNOWN ·Phase: NA
-
Comparison Between High-dose Amoxicillin Dual Therapy and Pylera Quadruple Therapy in the Treatment of Helicobacter Pylori Infection
NCT05100446 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea
NCT03665428 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion
NCT02051348 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection
NCT02835560 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide
NCT02090738 ·Status: WITHDRAWN ·Phase: PHASE2
-
Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection
NCT03521726 ·Status: COMPLETED ·Phase: PHASE4
-
Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy
NCT02894268 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
NCT05742568 ·Status: COMPLETED ·Phase: PHASE4
-
Intraluminal Therapy for Helicobacter Pylori Infection
NCT03124420 ·Status: COMPLETED ·Phase: PHASE4
-
Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
NCT03139253 ·Status: UNKNOWN ·Phase: PHASE4
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients
NCT03317223 ·Status: COMPLETED ·Phase: PHASE3
-
Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin
NCT05129176 ·Status: UNKNOWN ·Phase: PHASE4
-
Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection
NCT03516669 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection
NCT02483715 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)
NCT05997433 ·Status: RECRUITING ·Phase: NA
-
Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study
NCT06731023 ·Status: NOT_YET_RECRUITING
-
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
NCT00841854 ·Status: COMPLETED ·Phase: PHASE4